Recall Z-0722-2007

Abbott Laboratories Inc. · initiated January 30, 2007

Terminated

Product

Clinical Chemistry Phosphorus in vitro diagnostic, List Number: 7D71-30 and 7D71-20

Codes / lots: 42020HW00 & 44037HW00

Reason for recall

Patient results are falsely decreased by up to 15% at these levels: 1) Serum Plasma phosphorus greater than 8.0 mg/dL (2.60 mmol/L) 2) Urine phosphorus greater than 80.0 mg/dL (25.80 mmol/L)

FDA-determined cause: Other

Action taken

A Product Correction letter dated January 30, 2007 provided to all Clinical Chemistry Phosphorus customers that have received lot numbers 42020HW00 and 44037HW00 stating that patient results are falsely decreased by up to 15% at these levels: Serum/Plasma phosphorus greater than 8.0 mgldL (2.60 mmol/L) and Urine phosphorus greater than 80.0 mg/dl. (25.80 mmol/L). Modified linearity ranges are provided in the letter that are to be implemented when using the two lots. Instructions are also provided for changing the linearity range on the Architect cSystem as well as the Aeroset System. Customers are instructed that If they have forwarded any of Information the Clinical Chemistry Phosphorus lots listed above to another laboratory to provide a copy of this letter to them. A customer response form is provided.

Details

Recall number
Z-0722-2007
Initiated
January 30, 2007
Posted by FDA
April 5, 2007
Terminated
August 10, 2011
Product code
CEO – Phosphomolybdate (Colorimetric), Inorganic Phosphorus
Quantity
42020HW00 - 1,351 units worldwide; 44037HW00 - 314 units worldwide
Distribution
Worldwide, including USA, Canada, Trinidad & Tobago, Bahamas, Panama, Cayman Islands, Jamaica
Recalling firm
Abbott Laboratories Inc., South Pasadena, CA

Official FDA recall record